All In Biotech

Drug Trial Radar · NCT07218029

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-038)

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

815

Planned (sponsor's estimate)

Start

May 12, 2021

Primary completion

Dec 7, 2028

Study completion Dec 7, 2028

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart. PAH can make it hard to breathe and be active. Some standard (usual) treatments for PAH can treat symptoms of PAH but do not stop PAH from getting worse. Sotatercept is a study medicine designed to treat PAH. It is a targeted therapy, which is a treatment that works on certain proteins that play a role in causing PAH. This is a long-term follow-up (LTFU) study. People who took part in certain other studies testing sotatercept for PAH may be able to join this study. The goal of this study is to learn about the long-term safety of sotatercept and if people tolerate it when taken with standard PAH treatment over a longer period of time.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • SotaterceptBiological

    Sotatercept SC injection every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 90 months
  2. Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 86 months
  3. Number of Participants with Detectable Anti-Drug Antibodies (ADAs)Time frame: Up to approximately 88 months
  4. Laboratory parameters (Hematology): Concentration of Platelets and HemoglobinTime frame: Up to approximately 88 months
  5. Laboratory parameters (Chemistry): Concentration of Creatinine, Total Bilirubin, and Alanine Aminotransferase (ALT)Time frame: Up to approximately 86 months
  6. Change From Baseline in Body WeightTime frame: Baseline and up to approximately 86 months
  7. Change From Baseline in Blood PressureTime frame: Baseline and up to approximately 86 months
  8. Change From Baseline in Electrocardiogram (ECG)Time frame: Baseline and up to approximately 86 months

Locations

137 sites in 27 countries. Site status is shown where the registry gives one.

  • Pulmonary Associates, PA ( Site 1008)

    Phoenix, Arizona

  • Arizona Pulmonary Specialists ( Site 1010)

    Scottsdale, Arizona

  • University of Arizona ( Site 1006)

    Tucson, Arizona

  • University of California San Diego Health ( Site 1002)

    La Jolla, California

  • UC Irvine Health Medical Center ( Site 1086)

    Orange, California

  • UC Davis - Medial Center ( Site 1064)

    Sacramento, California

  • UCSF Helen Diller Medical Center at Parnassus Heights ( Site 1019)

    San Francisco, California

  • Jeffrey S. Sager, MD Medical Corporation ( Site 1060)

    Santa Barbara, California

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ( Site 1028)

    Torrance, California

  • University of Colorado Hospital ( Site 1013)

    Aurora, Colorado

  • George Washington University Medical Faculty Associates ( Site 1025)

    Washington D.C., District of Columbia

  • Mayo Clinic Jacksonville ( Site 1045)

    Jacksonville, Florida

  • AdventHealth Orlando ( Site 1058)

    Orlando, Florida

  • Tampa General Hospital ( Site 1043)

    Tampa, Florida

  • The Emory Clinic ( Site 1030)

    Atlanta, Georgia

  • University of Kansas Medical Center ( Site 1020)

    Kansas City, Kansas

  • Norton Pulmonary Specialists ( Site 1066)

    Louisville, Kentucky

  • Johns Hopkins University ( Site 1036)

    Baltimore, Maryland

  • Tufts Medical Center ( Site 1012)

    Boston, Massachusetts

  • Brigham and Women's Hospital ( Site 1014)

    Boston, Massachusetts

  • University of Minnesota ( Site 1062)

    Minneapolis, Minnesota

  • University Of Nebraska Medical Center ( Site 1053)

    Omaha, Nebraska

  • Weill Cornell Medical Center ( Site 1046)

    New York, New York

  • Duke University Medical Center ( Site 1026)

    Durham, North Carolina

  • The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001)

    Cincinnati, Ohio

  • University of Cincinnati Medical Center ( Site 1035)

    Cincinnati, Ohio

  • Cleveland Clinic Main ( Site 1065)

    Cleveland, Ohio

  • Ohio State University Wexner Medical Center ( Site 1032)

    Columbus, Ohio

  • Oregon Health & Science University ( Site 1054)

    Portland, Oregon

  • University of Pittsburgh Medical Center - Presbyterian Hosp. ( Site 1059)

    Pittsburgh, Pennsylvania

  • Rhode Island Hospital ( Site 1033)

    Providence, Rhode Island

  • Medical University of South Carolina ( Site 1003)

    Charleston, South Carolina

  • University of Texas Southwestern Medical Center ( Site 1038)

    Dallas, Texas

  • CHI St. Luke's Health Baylor College of Medicine Medical Center ( Site 1044)

    Houston, Texas

  • Houston Methodist Hospital ( Site 1009)

    Houston, Texas

  • Froedtert Hospital & the Medical College of Wisconsin ( Site 1051)

    Milwaukee, Wisconsin

  • Sanatorio Allende ( Site 1908)

    Córdoba, Argentina

  • Hospital Provincial Dr. Jose M. Cullen ( Site 1902)

    Santa Fe, Argentina

  • Instituto de Investigaciones Clinicas Quilmes ( Site 1903)

    Quilmes, Buenos Aires, Argentina

  • Instituto Médico Río Cuarto ( Site 1907)

    Río Cuarto, Córdoba Province, Argentina

Showing 40 of 137 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.